Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.92 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.92 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.92 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.92 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.92 |
| ▸ | TP53 | P04637 | 2/20 | 0.92 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.92 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.92 |
| ▸ | MAPT | P10636 | 2/20 | 0.92 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.92 |
| ▸ | TSHR | P16473 | 2/20 | 0.92 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.92 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.92 |
| ▸ | THPO | P40225 | 2/20 | 0.92 |
| ▸ | MTOR | P42345 | 2/20 | 0.92 |
| ▸ | RAB9A | P51151 | 2/20 | 0.92 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.92 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.92 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL726349 | 0.96 | SLC6A2 (1.00) | SIGMAR1SLC6A2SLC6A4SLC6A3SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL339982 | 0.94 | SMN1; SMN2 (1.00) | SIGMAR1SLC6A2SLC6A4SLC6A3SMN1; SMN2 | |
| SCHEMBL10000765 | 0.88 | SLC6A4 (0.97) | SIGMAR1SLC6A2SLC6A4SLC6A3SMN1; SMN2 | |
| Vanoxerine SCHEMBL246574 | 0.86 | SLC6A4 (1.00) | SIGMAR1SLC6A2SLC6A4SLC6A3SMN1; SMN2 | |
| SCHEMBL31420200 | 0.86 | SLC6A4 (0.82) | SIGMAR1SLC6A2SLC6A4SLC6A3SMN1; SMN2 | |
| SCHEMBL6517933 | 0.86 | SIGMAR1 (0.82) | SIGMAR1SLC6A2SLC6A4SLC6A3SMN1; SMN2 | |
| SCHEMBL6254945 | 0.86 | SLC6A4 (0.90) | SIGMAR1SLC6A2SLC6A4SLC6A3SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11374533 | 0.85 | SLC6A4 (0.90) | SIGMAR1SLC6A2SLC6A4SLC6A3SMN1; SMN2 | |
| Vanoxerine SCHEMBL725103 | 0.85 | SLC6A4 (1.00) | SIGMAR1SLC6A2SLC6A4SLC6A3SMN1; SMN2 | |
| Vanoxerine SCHEMBL15541249 | 0.85 | SLC6A4 (1.00) | SIGMAR1SLC6A2SLC6A4SLC6A3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379269-B1 | ADENOSINE A2A RECEPTOR ANTAGONISTS COMBINED WITH NEUROTROPHIC ACTIVITY COMPOUNDS IN THE TREATMENT OF PARKINSON'S DISEASE | NEUROSEARCH AS (DK) | 2009-03-04 | — | — | EP | disclosed |
| US-7160899-B2 | Adenosine A2A receptor antangonists combined with neurotrophic activity compounds in the treatment of Parkinson's disease | NEUROSEARCH A/S (DK) | 2007-01-09 | — | — | US | disclosed |
| US-20040097540-A1 | Adenosine a2a receptor antangonists combined with neurotrophic activity compounds in the treatment of parkinson's disease | NEUROSEARCH A/S (DK) | 2004-05-20 | — | — | US | disclosed |
| US-20040063742-A1 | Treatment of parkinson's disease by the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity | NEUROSEARCH A/S (DK) | 2004-04-01 | — | — | US | disclosed |
| EP-1379269-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS COMBINED WITH NEUROTROPHIC ACTIVITY COMPOUNDS IN THE TREATMENT OF PARKINSON'S DISEASE | NEUROSEARCH A/S (DK) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002080957-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS COMBINED WITH NEUROTROPHIC ACTIVITY COMPOUNDS IN THE TREATMENT OF PARKINSON'S DISEASE | NEUROSEARCH A/S (DK) | 2002-10-17 | — | — | WO | disclosed |
| US-6387389-B1 | Sustained-release derivatives of hydroxylated analogs of substituted 1-[2[bis(aryl)methoxy]ethyl]-piperazines and -homopiperazines and their use | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2002-05-14 | — | — | US | disclosed |
| EP-0937053-A1 | SUSTAINED-RELEASE DERIVATIVES OF HYDROXYLATED ANALOGS OF SUBSTITUTED 1- 2 BIS(ARYL)METHOXY]ETHYL]-PIPERAZINES AND -HOMOPIPERAZINES AND THEIR USE AS NONCOMPETITIVE ANTAGONISTS OF DOPAMINE REUPTAKE | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998018769-A1 | SUSTAINED-RELEASE DERIVATIVES OF HYDROXYLATED ANALOGS OF SUBSTITUTED 1-[2[BIS(ARYL)METHOXY]ETHYL]-PIPERAZINES AND -HOMOPIPERAZINES AND THEIR USE AS NONCOMPETITIVE ANTAGONISTS OF DOPAMINE REUPTAKE | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-05-07 | — | — | WO | disclosed |